A study of the medications given to patients with schizophrenia
finds that the newer drugs do not offer enough additional
benefits over first-generation drugs to offset the increased
To continue reading this article, you must login
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.